María Alcázar-Fabra

María Alcázar-Fabra

Auto-generated profile, based on publicly available information

María Alcázar-Fabra

Centro Andaluz de Biología del Desarrollo and CIBERER, Instituto de Salud Carlos III, Universidad Pablo de Olavide-CSIC-JA, Sevilla 41013, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Biochimica et Biophysica Acta (BBA) - Bioenergetics
Verified
Journal Article
Closed access
MAMaría Alcázar-Fabra
María Alcázar-Fabra
Plácido NavasPlácido Navas
Plácido Navas
GCGloria Teresa Brea Calvo
Gloria Teresa Brea Calvo

20 July 2018 in Essays in Biochemistry
Verified
Journal Article
Open access
PDF file
MAMaría Alcázar-Fabra
María Alcázar-Fabra
Eva TrevissonEva Trevisson
Eva Trevisson
GCGloria Teresa Brea Calvo
Gloria Teresa Brea Calvo
Primary Coenzyme Q deficiencies represent a group of rare conditions caused by mutations in one of the genes required in its biosynthetic pathway at the enzymatic or regulatory level. The associated clinical manifestations are highly heterogeneous and mainly affect central and peripheral nervous system, kidney, skeletal muscle and heart. Genotype–phenotype correlations are difficult to establish, mainly because of the reduced number of patients and the large variety of symptoms. In addition, mutations in the same COQ gene can cause different clinical pictures. Here, we present an updated and comprehensive review of the clinical manifestations associated with each of the pathogenic variants causing primary CoQ deficiencies.

1 September 2016 in Mitochondrion
Verified
Journal Article
Closed access
DYDèlia Yubero
Dèlia Yubero
RMRaquel Montero
Raquel Montero
Miguel A. MartinMiguel A. Martin
Miguel A. Martin
JMJulio Montoya
Julio Montoya
ARAntonia Ribes
Antonia Ribes
GCGloria Teresa Brea Calvo
Gloria Teresa Brea Calvo

10 July 2019 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
MLManuel J. Acosta Lopez
Manuel J. Acosta Lopez
Eva TrevissonEva Trevisson
Eva Trevisson
MCMarcella Canton
Marcella Canton
LVLuis Vazquez-fonseca
Luis Vazquez-fonseca
VMValeria Morbidoni
Valeria Morbidoni
LSLeonardo Salviati
Leonardo Salviati
Coenzyme Q (CoQ), a redox-active lipid, is comprised of a quinone group and a polyisoprenoid tail. It is an electron carrier in the mitochondrial respiratory chain, a cofactor of other mitochondrial dehydrogenases, and an essential antioxidant. CoQ requires a large set of enzymes for its biosynthesis; mutations in genes encoding these proteins cause primary CoQ deficiency, a clinically and genetically heterogeneous group of diseases. Patients with CoQ deficiency often respond to oral CoQ10supplementation. Treatment is however problematic because of the low bioavailability of CoQ10and the poor tissue delivery. In recent years, bypass therapy using analogues of the precursor of the aromatic ring of CoQ has been proposed as a promising alternative. We have previously shown using a yeast model that vanillic acid (VA) can bypass mutations ofCOQ6, a monooxygenase required for the hydroxylation of the C5 carbon of the ring. In this work, we have generated a human cell line lacking functionalCOQ6using CRISPR/Cas9 technology. We show that these cells cannot synthesize CoQ and display severe ATP deficiency. Treatment with VA can recover CoQ biosynthesis and ATP production. Moreover, these cells display increased ROS production, which is only partially corrected by exogenous CoQ, while VA restores ROS to normal levels. Furthermore, we show that these cells accumulate 3-decaprenyl-1,4-benzoquinone, suggesting that in mammals, the decarboxylation and C1 hydroxylation reactions occur before or independently of the C5 hydroxylation. Finally, we show thatCOQ6isoform c (transcript NM_182480) does not encode an active enzyme. VA can be produced in the liver by the oxidation of vanillin, a nontoxic compound commonly used as a food additive, and crosses the blood-brain barrier. These characteristics make it a promising compound for the treatment of patients with CoQ deficiency due toCOQ6mutations.

1 March 2024 in Science Advances
Verified
Journal Article
Open access
MEMencía Espinosa-Martínez
Mencía Espinosa-Martínez
MAMaría Alcázar-Fabra
María Alcázar-Fabra
DLDavid Landeira
David Landeira
Cell memory refers to the capacity of cells to maintain their gene expression program once the initiating environmental signal has ceased. This exceptional feature is key during the formation of mammalian organisms, and it is believed to be in part mediated by epigenetic factors that can endorse cells with the landmarks required to maintain transcriptional programs upon cell duplication. Here, we review current literature analyzing the molecular basis of epigenetic memory in mammals, with a focus on the mechanisms by which transcriptionally repressive chromatin modifications such as methylation of DNA and histone H3 are propagated through mitotic cell divisions. The emerging picture suggests that cellular memory is supported by an epigenetic cycle in which reversible activities carried out by epigenetic regulators in coordination with cell cycle transition create a multiphasic system that can accommodate both maintenance of cell identity and cell differentiation in proliferating stem cell populations.

20 April 2021 in BioFactors
Verified
Journal Article
Closed access
PDF file
Plácido NavasPlácido Navas
Plácido Navas
MCMaria Victoria Cascajo
Maria Victoria Cascajo
MAMaría Alcázar‐Fabra
María Alcázar‐Fabra
JHJuan D. Hernández‐Camacho
Juan D. Hernández‐Camacho
ASAna Sánchez‐Cuesta
Ana Sánchez‐Cuesta
Carlos Santos-OcañaCarlos Santos-Ocaña
Carlos Santos-Ocaña